Overview

Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
0
Participant gender:
Male
Summary
This trial is going to evaluate tumor control and quality of life in patients with prostate cancer treated with radiotherapy or cryoablation.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborators:
Peking University First Hospital
Shandong Cancer Hospital and Institute
Shanghai Jiao Tong University School of Medicine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Third Xiangya Hospital of Central South University
Tianjin First Central Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
Bicalutamide
Hormones
Prolactin Release-Inhibiting Factors
Criteria
Inclusion Criteria:

- Prostate adenocarcinoma, T3aN0M0, T3bN0M0

- Previously untreated disease or undergone endocrine therapy without reaching to
castration resistant prostate cancer

- Survival ≥ 12 months

- WHO performance status 0-2

- white blood cell ≥ 3.5 ×10*9/L

- Platelets ≥ 5×10*9/L

- Hemoglobin ≥ 10 g/dL

Exclusion Criteria:

- History of malignant disease

- History of coronary artery disease

- Uncontrolled infection

- Other concurrent severe or uncontrolled medical disease that could compromise
participation in the study (i.e., uncontrolled diabetes mellitus, uncontrolled cardiac
disease, uncontrolled hypertension, congestive cardiac failure, ventricular
arrhythmias, active ischemic heart disease, myocardial infarction within the past six
months, chronic liver or renal disease, and active upper gastrointestinal tract
ulceration)

- Psychological, familial, sociological, or geographical condition potentially hampering
compliance with the study treatment and follow-up schedule